Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Mar 11, 2026
- Closes
- Oct 11, 2029 (in 1092 days)
Similar opportunities open now
- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Oct 2027Up to $300K
- Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Nov 2029Up to $600K
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Jan 7, 2027 (in 84 days)Up to $500K
- Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Sep 2028
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jan 7, 2027 (in 84 days)
Classification and identifiers
- Solicitation number
- PAR-28-014
- Assistance listing (CFDA)
- 93.113
Amount
Amount not listed here. Check the official program.
Who can apply
Public colleges and universities can apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications that investigate the etiology of sporadic non-hereditary early-onset cancers (EOCs: ages 18 to 49 years) and the underlying biological mechanisms that play a role in these cancers to inform prevention and control strategies. The proposed research is expected to advance the understanding of the unexplained rise of cancers in young adults. More specifically, studies should address one or more of the following: i) what modifiable exposures are driving the increase in the incidence of non-hereditary EOCs, and how do these factors vary by patient demographics? (ii) what biological mechanisms and host responses underly the increase in EOCs? and (iii) how can those at increased risk for dev...